Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma).

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  D. Aguiar-Bujanda,et al.  Treatment of gastric marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone , 2014, Hematological oncology.

[3]  A. Olszewski,et al.  Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma , 2014, Annals of Hematology.

[4]  J. Thomalla,et al.  Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions , 2013, Leukemia & lymphoma.

[5]  Sharmila Binte Shamshad Ali Rn Dip.  Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia , 2013 .

[6]  A. Ng,et al.  Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Castillo,et al.  Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[9]  N. Schmitz,et al.  ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Castillo,et al.  Survival of patients with marginal zone lymphoma , 2013, Cancer.

[11]  P. Korkolopoulou,et al.  Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. , 2013, The oncologist.

[12]  S. Chevret,et al.  Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Copie-Bergman,et al.  Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[15]  L. Baldini,et al.  Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B‐cell nonfollicular lymphomas , 2012, Cancer.

[16]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[17]  D. Catovsky,et al.  Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL) , 2011 .

[18]  W. Fischbach,et al.  Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma. , 2011, Zeitschrift fur Gastroenterologie.

[19]  Derick R. Peterson,et al.  The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. , 2011, Blood.

[20]  A. López-Guillermo,et al.  Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Mazza,et al.  Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL) , 2011, Annals of Hematology.

[22]  C. Suh,et al.  Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. , 2010, World journal of gastroenterology.

[23]  E. Orciuolo,et al.  Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  E. Orciuolo,et al.  2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. , 2010, Leukemia research.

[25]  A. Salar,et al.  Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue type , 2009, Cancer.

[26]  J. Vose,et al.  Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Hassan,et al.  Eradication Therapy for Helicobacter pylori in Patients With Gastric MALT Lymphoma: A Pooled Data Analysis , 2009, The American Journal of Gastroenterology.

[28]  C. Copie-Bergman,et al.  Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial , 2009, British journal of haematology.

[29]  Tatsuya Nakamura,et al.  Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  D. de Jong,et al.  Long-term results of stomach-conserving therapy in gastric MALT lymphoma. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[32]  Hsiu‐Po Wang,et al.  Long-term Follow-up of Gastrectomized Patients With Mucosa-associated Lymphoid Tissue Lymphoma: Need for a Revisit of Surgical Treatment , 2008, Annals of surgery.

[33]  A. Banham,et al.  Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation , 2007, Gut.

[34]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  G. Schwarzer,et al.  Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.

[36]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. Do,et al.  Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone , 2006, Cancer.

[38]  T. Nazeer,et al.  Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas , 2006, Cancer.

[39]  N. Willich,et al.  Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Copie-Bergman,et al.  Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Pedrinis,et al.  Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Chott,et al.  Translocation t(11;18)(q21;q21) Is Not Predictive of Response to Chemotherapy with 2CdA in Patients with Gastric MALT Lymphoma , 2004, Oncology.

[43]  M. Herold,et al.  Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO) , 2004, Leukemia & lymphoma.

[44]  M. Stolte,et al.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series , 2003, Gut.

[45]  R. Tsang,et al.  Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Copie-Bergman,et al.  Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma , 2003, Gut.

[47]  T. Molina,et al.  Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes , 2003, British journal of haematology.

[48]  D. de Jong,et al.  Paris staging system for primary gastrointestinal lymphomas , 2003, Gut.

[49]  M. Piris,et al.  Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. , 2002, Blood.

[50]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[51]  G. Salles,et al.  Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. , 2002, Clinical lymphoma.

[52]  T. Molina,et al.  T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. , 2001, Gastroenterology.

[53]  N. Willich,et al.  Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  H. Müller-Hermelink,et al.  Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. , 2000, Gastroenterology.

[55]  A. Chott,et al.  Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma , 2000, British Journal of Cancer.

[56]  B. Gayet,et al.  Management and long-term results of surgery for localized gastric lymphomas. , 2000, American journal of surgery.

[57]  T. Chisesi,et al.  Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. , 2000, Blood.

[58]  H. Müller-Hermelink,et al.  Evaluation of Helicobacter pylori in gastric MALT-type lymphoma: differences between histologic and serologic diagnosis. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[59]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Yahalom,et al.  Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  W. Dickey,et al.  Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. , 1996, Alimentary pharmacology & therapeutics.

[63]  G. Flandrin,et al.  Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients , 1996, British journal of haematology.

[64]  P. Gaulard,et al.  Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  B. Coiffier,et al.  Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  D. Catovsky,et al.  Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases , 1991, British journal of haematology.

[67]  J. Melo,et al.  Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. , 1987, Journal of clinical pathology.

[68]  David H. Gustafson,et al.  Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes , 1976 .

[69]  F. Naeim.  33 – Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) , 2013 .

[70]  W. Klapper,et al.  The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) , 2009, Leukemia.

[71]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[72]  Y. Kodera,et al.  The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma. , 1998, Annals of surgery.

[73]  Ferguson Jh.  The NIH Consensus Development Program. The evolution of guidelines. , 1996 .

[74]  J. Ferguson.  The NIH Consensus Development Program: The Evolution of Guidelines , 1996, International Journal of Technology Assessment in Health Care.